Aussies urged to answer call for greatness in blood cancer battle as Leukaemia Foundation unites with Spartan
Thursday 5 December 2019
Aussies who dare take on the world’s top obstacle race course can now rise to the challenge of supporting those facing one of the toughest battles of all, with the Leukaemia Foundation combining forces with Spartan Race to tackle blood cancer.
For the first time ever, Spartans
Leukaemia Foundation joins Giving Tuesday Australia
Monday 2 December 2019
Generous Australians are encouraged to help the Leukaemia Foundation put a present under the Christmas Tree for children living with blood cancer as part of this year’s Giving Tuesday Australia.
Blood cancers like leukaemia and lymphoma remain the most commonly diagnosed childhood cancers in Australian children
Monash University’s Dr Khai Li Chai receives scholarship to further research into immunoglobulin therapy
Wednesday 27 November 2019
The Leukaemia Foundation and the Haematology Society of Australia and New Zealand (HSANZ) have collaborated to award Monash University PhD student Dr Khai Li Chai a three-year, $120,000 scholarship.
The funding will support Dr Chai’s research into hypogammaglobulinaemia in people living with a range of blood cancers:
Burden lightened for rural patients needing life-saving treatment
Friday 22 November 2019
The Leukaemia Foundation’s patient accommodation facilities in Townsville will continue to be a home away from home for blood cancer patients from rural and remote Queensland, following a sizable donation from the Freemasons.
As Aramac Masonic Lodge, some 550km away closed its doors for the last time
Vital cancer treatment now available through Pharmaceutical Benefits Scheme (PBS) for more Australians living with blood cancer
Wednesday 20 November 2019
The Leukaemia Foundation has welcomed news that cancer treatment, blinatumumab (Blincyto®) will be available for patients in the early stage of acute lymphoblastic leukaemia (ALL) who have minimal residual disease (MRD, through the Pharmaceuticals Benefits Scheme (PBS) effective December 1, 2019. A patient has MRD
Leukaemia Foundation HSANZ PhD scholarship for Monash University researcher
Monday 18 November 2019
The Leukaemia Foundation and the Haematology Society of Australia and New Zealand (HSANZ) are proud to announce Dr Liesl Butler from Monash University has been awarded a $120,000 New Investigator PhD scholarship for 2020.
The funding will support Dr Butler’s research into developing improved biomarkers and targeted
More than 35,000 Australians will unite for zero lives lost to blood cancer by 2035
Thursday October 10 2019
On Friday 11 October more than 35,000 Australians will unite to walk together to shine a light on blood cancer at the Leukaemia Foundation’s annual Light the Night event. For the first time, this year they’ll also be walking as one towards a bold new
Australians raise the bar for the Leukaemia Foundation’s U.G.L.Y Bartender of the Year
More than 800 bartenders across the country have come together to be ‘U.G.L.Y.’ for the Leukaemia Foundation’s U.G.L.Y. Bartender of the Year awards. The extraordinary group of Aussies raised a massive $920,000 to pay for 11,500 nights of accommodation, essential for regional families affected by blood cancer who must
Leukaemia Foundation supports latest Pharmaceutical Benefits Scheme (PBS) listings for blood cancer patients
Monday September 30 2019
The Leukaemia Foundation has welcomed news Australians living with Philadelphia chromosome B-cell precursor acute lymphocytic leukaemia (B-ALL) will now have access to treatment options blinatumumab (Blincyto®) and inotuzumab ozogamicin (Besponsa®) through the Pharmaceuticals Benefits Scheme (PBS) effective October 1, 2019.
Leukaemia Foundation CEO Bill Petch joined Federal
Australia’s National Blood Cancer Taskforce meets for first time
Monday September 30 2019
The Leukaemia Foundation established the Blood Cancer Taskforce with the support of the Federal Government to develop Australia’s first National Strategic Action Plan for Blood Cancer.
Co-chaired by Bill Petch (CEO, Leukaemia Foundation) and Professor John Seymour (Director of Cancer Medicine, Clinical Research and Haematology, Peter MacCallum